References
- Ernst T, Hochhaus A. Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression. Semin Oncol 2012;39:58–66.
- Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041–6051.
- Manrique Arechavaleta G, Scholl V, Pérez V, et al. Rapid and sensitive allele-specific (AS)-RT-PCR assay for detection of T315I mutation in chronic myeloid leukemia patients treated with tyrosine-kinase inhibitors. Clin Exp Med 2011;11:55–59.
- Branford S, Hughes TP. Mutational analysis in chronic myeloid leukemia: when and what to do?Curr Opin Hematol 2011;18:111–116.
- Branford S, Fletcher L, Cross NCP, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood, 2008;112:3330–3338.
- Nagar B, Hantschel O, Young MA, et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 2003;112:859–871.
- Schindler T, Bornmann W, Pellicena P, et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000;289: 1938–1942.
- Azam M, Daley GQ. Anticipating clinical resistance to target-directed agents: the BCR-ABL paradigm. Mol Diagn Ther 2006;10: 67–76.
- O’Hare T, Deininger MWN, Eide CA, et al. Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin Cancer Res 2011;17:212–221.
- Quintás-Cardama A, Cortes J. Molecular biology of bcr- abl1-positive chronic myeloid leukemia. Blood 2009;113:1619–1630.
- Terme M, Borg C, Guilhot F, et al. BCR/ABL promotes dendritic cell-mediated natural killer cell activation. Cancer Res 2005;65: 6409–6417.
- Itonaga H, Tsushima H, Hata T, et al. Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa. Int J Hematol 2012;95:209–213.
- Sherbenou DW, Wong MJ, Humayun A, et al. Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia 2007;21: 489–493.
- Soverini S, Gnani A, De Benedittis C, et al. Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib. Leuk Res 2011;35:1527–1529.
- Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012; 367:2075–2088.